Trump’s Big Bet On COVID-19 Vaccines May Have Shortchanged Therapeutics. Should Biden Rectify The Difference?

Incoming US President may be wise to up government investment in COVID-19 therapeutics, including both research and manufacturing, experts say. Additional government funding should target a larger variety of treatment types and prioritize better study designs.

Golden stacked coins on justice scale
What's the right balance in funding development of COVID vaccines and therapeutics?

The US government has invested about four and a half times as much money in the development and manufacturing of potential COVID-19 vaccines to prevent the disease as it has on therapeutics to treat the coronavirus, and experts say President-elect Joe Biden’s team should work to close this gap, though few recommend spending on treatments at the same level as vaccines.

The Biomedical Advanced Research and Development Authority has provided more than $12.6bn to vaccines, more than $2

More from Elections

More from Legislation